Tag: Pharmacoeconomics

Studies show that approximately 90% of all new drugs that enter clinical trials ultimately fail to gain FDA approval, highlighting the high-risk nature of pharmaceutical development [1.2.1, 1.2.3, 1.2.5]. This article explores what the FDA approval rate for drugs is and the factors that influence it.

For the average patient, the annual list price of Cerezyme (imiglucerase) is approximately $200,000, though this figure can vary significantly based on dosage, disease severity, and individual factors. This high cost is typical for specialized orphan drugs designed to treat rare genetic disorders like Gaucher disease.

According to manufacturer Biogen, the wholesale acquisition cost for a single vial of Qalsody (tofersen) is $14,230. This puts the first-year list price for tofersen at nearly $200,000, creating significant discussion around the cost of this rare disease treatment.

With a price tag of **$4.25 million** for a one-time dose, Lenmeldy is currently the most expensive prescription drug in the world [1.2.2, 1.4.1, 1.4.3]. This article explores what the most expensive prescription drug in the world is and the factors driving its multimillion-dollar cost.

With an average annual cost potentially exceeding $600,000 per patient, the price of TAKHZYRO is staggering. An investigation into why is TAKHZYRO so expensive reveals a complex interplay of pharmaceutical economics, research, and market dynamics that drive up the cost of this life-changing, but incredibly expensive, medication for hereditary angioedema (HAE).

As of late 2024, the list price for a box of Nayzilam containing two doses was around $667, depending on the source. Many people wonder **why is Nayzilam so expensive?**, especially when the active ingredient, midazolam, is available in much cheaper generic forms. Several complex factors contribute to this high cost, primarily tied to its status as a novel, brand-name drug with market exclusivity.

In 2023, the U.S. spent $99 billion on anticancer therapies, a figure projected to hit $180 billion by 2028 [1.9.3]. Answering 'What is the most expensive chemotherapy drug?' now involves looking beyond traditional chemotherapy to advanced, multi-million dollar gene therapies.